Galderma Group AG
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
- Conditions
- Glabellar Frown Lines
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 401
- Registration Number
- NCT03736928
- Locations
- 🇺🇸
Galderma Research Site, Mequon, Wisconsin, United States
GAL1704 for Cheek Augmentation and Correction of Midface Contour Deficiencies
- Conditions
- Cheek Augmentation
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 270
- Registration Number
- NCT03700047
- Locations
- 🇺🇸
Galderma Study site, Dallas, Texas, United States
🇺🇸Galderma Study Site, Salt Lake City, Utah, United States
🇺🇸Galderma study site, Bellaire, Texas, United States
Subject Satisfaction With AbobutulinumtoxinA Treatment
- Conditions
- Glabellar Frown Lines
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 120
- Registration Number
- NCT03687736
- Locations
- 🇺🇸
Galderma Study Site, Omaha, Nebraska, United States
A Study to Evaluate the Safety and Efficacy of Restylane Defyne for Chin Augmentation and Correction of Chin Retrusion
- Conditions
- Chin RetrusionChin Augmentation
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 140
- Registration Number
- NCT03624816
- Locations
- 🇺🇸
Westside Aesthetics, Los Angeles, California, United States
🇺🇸Ablon Skin Institute and Research Center, Manhattan Beach, California, United States
🇺🇸Marcus Facial Plastic Surgery, Redondo Beach, California, United States
Restylane Defyne for Correction of Chin Retrusion
- Conditions
- Chin Retrusion
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 148
- Registration Number
- NCT03597256
- Locations
- 🇨🇳
Galderma Research Site, Shanghai, Shanghai, China
PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK
- Conditions
- Actinic Keratoses
- Interventions
- Drug: Methyl Aminolaevulinate 16% Cream
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 50
- Registration Number
- NCT03511326
- Locations
- 🇩🇪
University Hospital Regensburg, Regensburg, Germany
New Dermal Filler for Lip Augmentation
- Conditions
- Lip Augmentation
- First Posted Date
- 2017-10-25
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 273
- Registration Number
- NCT03320824
- Locations
- 🇺🇸
Clinical Testing of Bevelry Hills, Encino, California, United States
🇺🇸Cosmetic Laser Dermatology, San Diego, California, United States
🇺🇸Art of Skin MD, Solana Beach, California, United States
A Study to Evaluate the Performance and Safety of GP0045 for Correction of Moderate to Severe Nasolabial Folds
- Conditions
- Nasolabial FoldSafety
- First Posted Date
- 2017-10-03
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 20
- Registration Number
- NCT03300466
- Locations
- 🇸🇪
Q-Med, Uppsala, Sweden
A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)
- Conditions
- Cutaneous T Cell Lymphoma
- Interventions
- Drug: CD11301 0.03%Drug: PlaceboDrug: CD11301 0.06%
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 86
- Registration Number
- NCT03292406
- Locations
- 🇩🇪
Galderma Investigational Site, Berlin, Germany
Restylane Volyme for Correction of Midface Volume Deficit and/or Midface Contour Deficiency
- Conditions
- Midface Volume Deficit
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 168
- Registration Number
- NCT03289052
- Locations
- 🇨🇳
Q-Med AB, Shanghai, China